Literature DB >> 27092797

Tumor-necrosis factor is a master of T cell exhaustion.

Amy E Baxter1, Daniel E Kaufmann1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27092797     DOI： 10.1038/ni.3436

Source DB:  PubMed          Journal:  Nat Immunol        ISSN： 1529-2908            Impact factor:   25.606


× No keyword cloud information.
  10 in total

Review 1.  Nonpathogenic simian immunodeficiency virus infections.

Authors:  Nichole R Klatt; Guido Silvestri; Vanessa Hirsch
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

2.  Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone.

Authors:  T M Folks; K A Clouse; J Justement; A Rabson; E Duh; J H Kehrl; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

3.  PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression.

Authors:  Cheryl L Day; Daniel E Kaufmann; Photini Kiepiela; Julia A Brown; Eshia S Moodley; Sharon Reddy; Elizabeth W Mackey; Joseph D Miller; Alasdair J Leslie; Chantal DePierres; Zenele Mncube; Jaikumar Duraiswamy; Baogong Zhu; Quentin Eichbaum; Marcus Altfeld; E John Wherry; Hoosen M Coovadia; Philip J R Goulder; Paul Klenerman; Rafi Ahmed; Gordon J Freeman; Bruce D Walker
Journal:  Nature       Date:  2006-08-20       Impact factor: 49.962

Review 4.  Molecular and cellular insights into T cell exhaustion.

Authors:  E John Wherry; Makoto Kurachi
Journal:  Nat Rev Immunol       Date:  2015-08       Impact factor: 53.106

5.  Blockade of chronic type I interferon signaling to control persistent LCMV infection.

Authors:  Elizabeth B Wilson; Douglas H Yamada; Heidi Elsaesser; Jonathan Herskovitz; Jane Deng; Genhong Cheng; Bruce J Aronow; Christopher L Karp; David G Brooks
Journal:  Science       Date:  2013-04-12       Impact factor: 47.728

6.  Persistent LCMV infection is controlled by blockade of type I interferon signaling.

Authors:  John R Teijaro; Cherie Ng; Andrew M Lee; Brian M Sullivan; Kathleen C F Sheehan; Megan Welch; Robert D Schreiber; Juan Carlos de la Torre; Michael B A Oldstone
Journal:  Science       Date:  2013-04-12       Impact factor: 47.728

7.  Tumor-necrosis factor impairs CD4(+) T cell-mediated immunological control in chronic viral infection.

Authors:  Marc Beyer; Zeinab Abdullah; Jens M Chemnitz; Daniela Maisel; Jil Sander; Clara Lehmann; Yasser Thabet; Prashant V Shinde; Lisa Schmidleithner; Maren Köhne; Jonel Trebicka; Robert Schierwagen; Andrea Hofmann; Alexey Popov; Karl S Lang; Annette Oxenius; Thorsten Buch; Christian Kurts; Mathias Heikenwalder; Gerd Fätkenheuer; Philipp A Lang; Pia Hartmann; Percy A Knolle; Joachim L Schultze
Journal:  Nat Immunol       Date:  2016-03-07       Impact factor: 25.606

8.  Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy: persistent TNF activation is associated with virologic and immunologic treatment failure.

Authors:  P Aukrust; F Müller; E Lien; I Nordoy; N B Liabakk; D Kvale; T Espevik; S S Froland
Journal:  J Infect Dis       Date:  1999-01       Impact factor: 5.226

9.  Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B.

Authors:  L Osborn; S Kunkel; G J Nabel
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

10.  Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection--correlations to clinical, immunologic, and virologic parameters.

Authors:  P Aukrust; N B Liabakk; F Müller; E Lien; T Espevik; S S Frøland
Journal:  J Infect Dis       Date:  1994-02       Impact factor: 5.226
  10 in total
  3 in total

1.  Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNFα-antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure.

Authors:  Hilal Hachem; Amandeep Godara; Courtney Schroeder; Daniel Fein; Hashim Mann; Christian Lawlor; Jill Marshall; Andreas Klein; Debra Poutsiaka; Janis L Breeze; Raghav Joshi; Paul Mathew
Journal:  J Clin Transl Sci       Date:  2021-06-25

2.  In vivo immune signatures of healthy human pregnancy: Inherently inflammatory or anti-inflammatory?

Authors:  Caroline Graham; Rishma Chooniedass; William P Stefura; Allan B Becker; Malcolm R Sears; Stuart E Turvey; Piush J Mandhane; Padmaja Subbarao; Kent T HayGlass
Journal:  PLoS One       Date:  2017-06-21       Impact factor: 3.240

3.  Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T-cell phenotype.

Authors:  Patrick Harrington; Richard Dillon; Deepti Radia; Donal McLornan; Claire Woodley; Susan Asirvatham; Kavita Raj; Natalia Curto-Garcia; Jamie Saunders; Shahram Kordasti; Claire Harrison; Hugues de Lavallade
Journal:  Br J Haematol       Date:  2022-07-08       Impact factor: 8.615
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.